Oncology News | pharmaphorum

News

Views & Analysis

How data is crucial to the relaunch of the Cancer Moonshot

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot.

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

News

UK's Pheon is latest kid on the block in ADC sector

There's a new player on the antibody-drug conjugate (ADC) scene.

News

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

Japan's Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T

News

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

News

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted

How data is crucial to the relaunch of the Cancer Moonshot

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

UK's Pheon is latest kid on the block in ADC sector

Daiichi Sankyo grabs first approval for blood cancer drug Ez...

Routine NHS access to Ibrance assured with new NICE guidance

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks